Brussels (Belgium), 20 January 2020 – 20:05 (CET) – regulated informationIn application of article 8:6 of the Royal Decree executing the new Belgian Code of Companies and Associations, UCB SA/NV announces that following exercises of stock options by its employees, it has disposed of UCB shares OTC in view of deliveries of shares to the relevant employees, within the framework of the Long Term Incentive Program of the UCB Group, as follows:
This press release is available on UCB SA/NV’s website via the following
link.
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com
About UCB
UCB,
Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines and
solutions to transform the lives of people living with severe diseases
of the immune system or of the central nervous system. With 7 500 people
in approximately 40 countries, the company generated revenue of € 4.6
billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB).
Follow us on Twitter: @UCB_news